MyoKardia, Inc. (NASDAQ:MYOK) produced a 16.39% rally since recording the worst price of $39.16. Thanks to the latest 3.8% increase, it now trades at $45.58. Throughout the trading on 01/09/2019, the share price floated between $44.51 and $48.38. This company shares are 70.16% off its target price of $77.56 and the current market capitalization stands at $1.82B. The recent change has given its price a -15.2% deficit over SMA 50 and -32.76% deficit over its 52-week high. The stock witnessed -20.12% declines, -14.58% declines and -16.14% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found MYOK’s volatility during a week at 8.62% and during a month it has been found around 7.41%.MyoKardia, Inc. (MYOK) Top Holders
Institutional investors currently hold around $1.58 billion or 90.6% in MYOK stock. Look at its top three institutional owners. Fmr Llc owns $264.22 million in MyoKardia, Inc., which represents roughly 14.52% of the company’s market cap and approximately 16.78% of the institutional ownership. Similar statistics are true for the second largest owner, Wellington Management Group Llp, which owns 3,148,683 shares of the stock are valued at $138.26 million. The third largest holder is Vanguard Group Inc, which currently holds $131.55 million worth of this stock and that ownership represents nearly 7.23% of its market capitalization.MyoKardia, Inc. 13F Filings
At the end of September reporting period, 69 institutional holders increased their position in MyoKardia, Inc. (NASDAQ:MYOK) by some 2,592,868 shares, 55 decreased positions by 2,043,843 and 17 held positions by 31,237,188. That puts total institutional holdings at 35,873,899 shares, according to SEC filings. The stock grabbed 19 new institutional investments totaling 310,474 shares while 15 institutional investors sold out their entire positions totaling 490,194 shares.MyoKardia, Inc. (NASDAQ:MYOK) Insider Trades
Multiple company employees have indulged in significant insider trading. MyoKardia, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that President and CEO Gianakakos Anastasios has acquired 2,500 shares of MyoKardia, Inc. (MYOK) in trading session dated Jan. 04, 2019. These shares are worth $99,650 and were traded at $39.86 each. The SEC filing shows that Gianakakos Anastasios performed a sale of 3,000 shares. The President and CEO disposed these shares by way of transaction on Dec. 12, 2018. The company’s shares were given away at $55.68 per share worth to an income of some $167,040 on account of Gianakakos Anastasios.
, Lee June, sold 5,000 common shares of MyoKardia, Inc. (MYOK) in the open market. In a transaction dated Dec. 03, 2018, the shares were put up for sale at an average price of $60.81, raking in a sum of $304,050. After this sale, 770 common shares of MYOK are directly owned by the insider, with total stake valued at $35,097.
In the transaction dated Nov. 05, 2018, the great number of shares disposed came courtesy the President and CEO; Gianakakos Anastasios disposed a total of 3,000 shares at an average price of $56.57, amounting to approximately $169,710. The insider now directly owns 697,660 shares worth $31,799,343.MyoKardia, Inc. (MYOK) Analyst Guide
Several analysts have released their opinion on MyoKardia, Inc. (NASDAQ:MYOK), with 4 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 5 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.56 average brokerage recommendation.